Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 90, No 6 (2019)
Research paper
Published online: 2019-06-28
View PDF Download PDF file
Get Citation

Comparison of the diagnostic value of histopathological examinations of miscarriage products after pharmacological induction of miscarriage and curettage

Jakub Sliwa1, Anna Kryza-Ottou1, Anna Rosner-Tenerowicz1, Maciej Kaczorowski2, Mariusz Zimmer1, Zygmunt Domagala3
DOI: 10.5603/GP.2019.0061
·
Pubmed: 31276185
·
Ginekol Pol 2019;90(6):331-335.
Affiliations
  1. Departament of Obstetrics and Gynecology, Medical University of Wroclaw, Poland
  2. Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Wroclaw, Poland
  3. Department of Anatomy, Morphology and Human Embryology, Wroclaw Medical University, Wroclaw, Poland

open access

Vol 90, No 6 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-06-28

Abstract

Objectives: For early miscarriage (pregnancy loss ≤ 12 weeks of gestation), two types of therapeutic treatment are offered (pharmacotherapy and curettage of the uterine cavity) depending on the presence and severity of clinical symptoms as well as patient choice. Our study aimed to assess the diagnostic value of the results of histopathological examinations of miscarriage products in relation to the administered treatments. 

Material and methods: 850 medical records from patients diagnosed with missed miscarriage or empty gestational sac were analyzed retrospectively. Patients underwent surgical treatment or pharmacotherapy. Inefficacy of pharmacotherapy resulted in subsequent curettage. The results of histopathology were evaluated for their diagnostic value and classified: subgroup 1 — high value specimen (the studied specimen included fetal tissues, and villi), and subgroup 2 — no-diagnosis (the studied specimen included maternal tissues, autolyzed tissues, blood clots). Data were compared with chi-squared test. Differences was considered significant at p < 0.05. 

Results: 1128 histopathological test results were analyzed; 569 (50.4%) were obtained during pharmacotherapy and 559 (49.6%) after curettage; out of the latter 497 after the initial pharmacotherapy and 62 after surgery. In the pharmacotherapy group, high value specimens comprised 231 cases (40.59%) while no diagnosis was obtained in 338 cases (59.4%). Considering specimens obtained in the course curettage, high value specimens were found in 364 cases (65.1%) while results that did not allow a diagnosis to be made were found in 195 cases (34.9%). 

Conclusions: Tissue specimens of high diagnostic value are obtained significantly more often during surgical treatment of miscarriage than during pharmacotherapy.

Abstract

Objectives: For early miscarriage (pregnancy loss ≤ 12 weeks of gestation), two types of therapeutic treatment are offered (pharmacotherapy and curettage of the uterine cavity) depending on the presence and severity of clinical symptoms as well as patient choice. Our study aimed to assess the diagnostic value of the results of histopathological examinations of miscarriage products in relation to the administered treatments. 

Material and methods: 850 medical records from patients diagnosed with missed miscarriage or empty gestational sac were analyzed retrospectively. Patients underwent surgical treatment or pharmacotherapy. Inefficacy of pharmacotherapy resulted in subsequent curettage. The results of histopathology were evaluated for their diagnostic value and classified: subgroup 1 — high value specimen (the studied specimen included fetal tissues, and villi), and subgroup 2 — no-diagnosis (the studied specimen included maternal tissues, autolyzed tissues, blood clots). Data were compared with chi-squared test. Differences was considered significant at p < 0.05. 

Results: 1128 histopathological test results were analyzed; 569 (50.4%) were obtained during pharmacotherapy and 559 (49.6%) after curettage; out of the latter 497 after the initial pharmacotherapy and 62 after surgery. In the pharmacotherapy group, high value specimens comprised 231 cases (40.59%) while no diagnosis was obtained in 338 cases (59.4%). Considering specimens obtained in the course curettage, high value specimens were found in 364 cases (65.1%) while results that did not allow a diagnosis to be made were found in 195 cases (34.9%). 

Conclusions: Tissue specimens of high diagnostic value are obtained significantly more often during surgical treatment of miscarriage than during pharmacotherapy.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

curettage; miscarriage; spontaneous abortion; histology; differential diagnosis

About this article
Title

Comparison of the diagnostic value of histopathological examinations of miscarriage products after pharmacological induction of miscarriage and curettage

Journal

Ginekologia Polska

Issue

Vol 90, No 6 (2019)

Article type

Research paper

Pages

331-335

Published online

2019-06-28

Page views

1946

Article views/downloads

1134

DOI

10.5603/GP.2019.0061

Pubmed

31276185

Bibliographic record

Ginekol Pol 2019;90(6):331-335.

Keywords

curettage
miscarriage
spontaneous abortion
histology
differential diagnosis

Authors

Jakub Sliwa
Anna Kryza-Ottou
Anna Rosner-Tenerowicz
Maciej Kaczorowski
Mariusz Zimmer
Zygmunt Domagala

References (33)
  1. Poland BJ, Miller JR, Jones DC, et al. Reproductive counseling in patients who have had a spontaneous abortion. Am J Obstet Gynecol. 1977; 127(7): 685–691.
    PubMed
  2. WARBURTON D, FRASER FC. SPONTANEOUS ABORTION RISKS IN MAN: DATA FROM REPRODUCTIVE HISTORIES COLLECTED IN A MEDICAL GENETICS UNIT. Am J Hum Genet. 1964; 16: 1–25.
    PubMed
  3. Doubilet PM, Benson CB, Bourne T, et al. Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy, Society of Radiologists in Ultrasound Multispecialty Panel on Early First Trimester Diagnosis of Miscarriage and Exclusion of a Viable Intrauterine Pregnancy. Diagnostic criteria for nonviable pregnancy early in the first trimester. N Engl J Med. 2013; 369(15): 1443–1451.
    CrossRefPubMed
  4. Lemmers M, Verschoor MAC, Bossuyt PM, et al. MisoREST study group. Cost-effectiveness of curettage vs. expectant management in women with an incomplete evacuation after misoprostol treatment for first-trimester miscarriage: a randomized controlled trial and cohort study. Acta Obstet Gynecol Scand. 2018; 97(3): 294–300.
    CrossRefPubMed
  5. Kim C, Barnard S, Neilson JP, et al. Medical treatments for incomplete miscarriage. Cochrane Database Syst Rev. 2017; 1: CD007223.
    CrossRefPubMed
  6. Demetroulis C, Saridogan E, Kunde D, et al. A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. Hum Reprod. 2001; 16(2): 365–369.
    CrossRefPubMed
  7. Alsibiani SA. Value of histopathologic examination of uterine products after first-trimester miscarriage. Biomed Res Int. 2014; 2014: 863482.
    CrossRefPubMed
  8. Tomasik P, Zwierzchowska A, Barcz E. Assessment of patient acceptability of medical treatment in case of non-viable first trimester pregnancy. Ginekol Pol. 2015; 86(5): 383–387.
    PubMed
  9. Luise C, Jermy K, May C, et al. Outcome of expectant management of spontaneous first trimester miscarriage: observational study. BMJ. 2002; 324(7342): 873–875.
    CrossRefPubMed
  10. Jurkovic D, Ross JA, Nicolaides KH. Expectant management of missed miscarriage. Br J Obstet Gynaecol. 1998; 105(6): 670–671.
    PubMed
  11. Bagratee JS, Khullar V, Regan L, et al. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod. 2004; 19(2): 266–271.
    CrossRefPubMed
  12. Ngai SW, Chan YM, Tang OS, et al. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Hum Reprod. 2001; 16(7): 1493–1496.
    CrossRefPubMed
  13. Novak RW, Malone JM, Robinson HB. The role of the pathologist in the evaluation of first trimester abortions. Pathol Annu. 1990; 25 Pt 1: 297–311.
    PubMed
  14. Rashid P. The role of histopathological examination of the products of conception following first-trimester miscarriage in Erbil Maternity Hospital. Zanco Journal of Medical Sciences. 2017; 21(3): 1938–1942.
    CrossRef
  15. Tasci Y, Dilbaz S, Secilmis O, et al. Routine histopathologic analysis of product of conception following first-trimester spontaneous miscarriages. J Obstet Gynaecol Res. 2005; 31(6): 579–582.
    CrossRefPubMed
  16. Yap SJ, Watts JC, Faithfull TJ, et al. Is tissue an issue? Current practice and opinion in Western Australia for routine histopathology on products of conception. Aust N Z J Obstet Gynaecol. 2014; 54(5): 493–496.
    CrossRefPubMed
  17. Szulman AE, Ma HK, Wong LC, et al. Residual trophoblastic disease in association with partial hydatidiform mole. Obstet Gynecol. 1981; 57(3): 392–394.
    PubMed
  18. Bagshawe KD, Lawler SD, Paradinas FJ, et al. Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet. 1990; 335(8697): 1074–1076.
    PubMed
  19. Hinshaw K, Fayyad A, Munjuluri P. The management of early pregnancy loss. http://www.jsog.org/GuideLines/The_management_of_early_pregnancy_loss.pdf (25.04.2018).
  20. Fram KM. Histological analysis of the products of conception following first trimester abortion at Jordan University Hospital. Eur J Obstet Gynecol Reprod Biol. 2002; 105(2): 147–149.
    PubMed
  21. Heath V, Chadwick V, Cooke I, et al. Should tissue from pregnancy termination and uterine evacuation routinely be examined histologically? BJOG. 2000; 107(6): 727–730.
    PubMed
  22. Jauniaux E, Kadri R, Hustin J. Partial mole and triploidy: screening patients with first-trimester spontaneous abortion. Obstet Gynecol. 1996; 88(4 Pt 1): 616–619.
    PubMed
  23. Gal A, Stenning H. Pitfalls in the diagnosis of ectopic pregnancy. Med J Aust. 1985; 143(9): 411–412.
    PubMed
  24. NICE. Ectopic pregnancy and miscarriage: diagnosis and initial management. Clinical guideline [CG154]. https://www.nice.org.uk/guidance/cg154/resources/surveillance-report-2017-ectopic-pregnancy-and-miscarriage-diagnosis-and-initial-management-2012-nice-guideline-cg154-4367146717/chapter/Surveillance-decision 2012 (30.07.2018).
  25. Cox P, Evans C. Tissue pathway for histopathological examination of the placenta. http://www.rcpath.org/publications-media/publications/datasets/tissue-pathway-placenta (30.06.2018).
  26. NHS Commissioning Board. E12/S/b - 2013/14 NHS Standard Contract for Perinatal Pathology. https://www.england.nhs.uk/wp-content/uploads/2013/06/e12-perinatal-path.pdf 2013 (30.06.2018).
  27. Petersen SG, Perkins AR, Gibbons KS, et al. The medical management of missed miscarriage: outcomes from a prospective, single-centre, Australian cohort. Med J Aust. 2013; 199(5): 341–346.
    PubMed
  28. Sur SD, Raine-Fenning NJ. The management of miscarriage. Best Pract Res Clin Obstet Gynaecol. 2009; 23(4): 479–491.
    CrossRefPubMed
  29. Petrou S, Trinder J, Brocklehurst P, et al. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ. 2006; 332(7552): 1235–1240.
    CrossRefPubMed
  30. Sotiriadis A, Makrydimas G, Papatheodorou S, et al. Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol. 2005; 105(5 Pt 1): 1104–1113.
    CrossRefPubMed
  31. Graziosi GCM, Bruinse HW, Reuwer PJH, et al. Misoprostol versus curettage in women with early pregnancy failure: impact on women's health-related quality of life. A randomized controlled trial. Hum Reprod. 2005; 20(8): 2340–2347.
    CrossRefPubMed
  32. Kitange B, Matovelo D, Konje E, et al. Hydatidiform moles among patients with incomplete abortion in Mwanza City, North western Tanzania. Afr Health Sci. 2015; 15(4): 1081–1086.
    CrossRefPubMed
  33. Biscaro A, Silveira SK, Locks Gd, et al. [Frequency of hydatidiform mole in tissue obtained by curettage]. Rev Bras Ginecol Obstet. 2012; 34(6): 254–258.
    PubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl